Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1942378799
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
6400 Fannin St Ste 2900
Houston, TX, 77030
Phone (713) 704-3961
Groups this clinician bills Medicare through
Medicare paid, 2024
$21K
230 services
Medicare patients, 2024
74
Average age 72
Drug cost, 2024
$7.8M
1,230 prescriptions
Company payments, 2025
$11K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Adan A Rios was code 99233 (hospital e&m - subsequent), 89 times for 17 patients. In total Adan A Rios billed 230 services in 8 codes, and Medicare paid $21K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 89 | 17 | $93.95 | $8,361 |
| 99214 Office E&M - Established | Office | 78 | 44 | $68.27 | $5,325 |
By year: 2022 $36K for 416 services; 2023 $16K for 178 services; 2024 $21K for 230 services.
Medicare prescription drug claims, 2024
In 2024, the drug Adan A Rios prescribed most often to Medicare patients was Calquence (Acalabrutinib Maleate), with 120 prescriptions and refills. In total Adan A Rios wrote 1,230 Medicare prescriptions that cost $7.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | 120 | 120 | 13 | $1.7M |
| Valacyclovir Valacyclovir Hcl | 108 | 152 | 30 | $6,858 |
| Levofloxacin Generic | 84 | 92 | 25 | $1,237 |
| Revlimid Lenalidomide | 76 | 76 | 13 | $1.2M |
| Lenalidomide Generic | 65 | 65 | 12 | $901K |
| Fluconazole Generic | 50 | 66 | 14 | $1,970 |
| Dexamethasone Generic | 38 | 62 | 13 | $739 |
| Prednisone Generic | 36 | 40 | 13 | $64.47 |
| Onureg Azacitidine | 31 | 31 | Under 11 | $795K |
| Venclexta Venetoclax | 30 | 30 | 15 | $40K |
| Dapsone Generic | 29 | 57 | Under 11 | $2,386 |
| Xospata Gilteritinib Fumarate | 26 | 26 | Under 11 | $365K |
| Potassium Chloride Generic | 25 | 31 | Under 11 | $147 |
| Cefdinir Generic | 24 | 26 | Under 11 | $1,906 |
| Pomalyst Pomalidomide | 23 | 23 | Under 11 | $642K |
Brand drugs: 475 claims; generic drugs: 755 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Adan A Rios $11K ($11K in general payments such as food, travel and fees) from 8 companies. The largest payer was Kite Pharma, Inc. with $8,569.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.